People living with hormone receptor‑positive breast cancer, endometriosis and adenomyosis are facing new uncertainty after confirmation that a medication many rely on will be taken off the market in Australia.
People living with hormone receptor‑positive breast cancer, endometriosis and adenomyosis are facing new uncertainty after confirmation that a medication many rely on will be taken off the market in Australia.